Which biomarker tests (ER/PR, HER2) are recommended for my Breast Cancer, and how will the results guide my...

Biomarker Testing for Breast Cancer: What You Need to Know

Great question! Biomarker testing is one of the most important steps in planning your breast cancer treatment. Let me explain what tests are recommended and how they guide your care.

What Biomarker Tests Are Recommended?

According to NCCN Guidelines for Invasive Breast Cancer, your care team will recommend testing for three key biomarkers on your tumor biopsy sample:

1. Estrogen Receptor (ER) Status

• What it is: A protein on cancer cells that responds to the hormone estrogen
• What it means: When estrogen attaches to ER receptors, it can cause cancer cells to grow and divide
• ER-Positive (ER+): Cancer cells have estrogen receptors in at least 1 out of every 100 cells
• ER-Low Positive: Only 1-10 out of every 100 cells have receptors (may affect treatment recommendations)
• ER-Negative: Cancer cells lack estrogen receptors

2. Progesterone Receptor (PR) Status

• What it is: A protein that responds to the hormone progesterone
• What it means: PR expression suggests the tumor is estrogen-dependent and may respond to hormone-blocking treatments
• PR-Positive (PR+): Cancer cells have progesterone receptors
• PR-Negative: Cancer cells lack progesterone receptors

3. HER2 Status

• What it is: Human epidermal growth factor receptor 2—a protein involved in cell growth
• What it means: Some breast cancers have too many HER2 genes or receptors (called HER2-positive or HER2 overexpression/amplification)
• HER2-Positive (HER2+): High levels of HER2 protein
• HER2-Negative (HER2-): Low or absent HER2 protein
• Testing method: Two tests may be used:
  • Immunohistochemistry (IHC): Stains cells to measure receptors (score of 3+ = HER2+)
  • In situ hybridization (ISH): Counts HER2 gene copies (done when IHC results are unclear)

---

How Results Guide Your Treatment Plan

Your hormone receptor status and HER2 status together determine which treatments are most likely to work for you. Here's how:

Hormone Receptor-Positive (HR+) Breast Cancer

This includes ER+ and/or PR+ cancers

Clinical approach: According to NCCN Guidelines, HR+ cancers are typically treated with endocrine therapy (hormone-blocking treatments) because:

• These cancers depend on estrogen to grow
• Blocking estrogen signals can stop cancer growth or cause cancer cells to die
• This is often the first-line treatment approach

Treatment options may include:

• Aromatase inhibitors (block estrogen production)
• Tamoxifen (blocks estrogen receptors)
• Fulvestrant (destroys estrogen receptors)
• CDK4/6 inhibitors (often combined with hormone therapy)

HER2-Positive (HER2+) Breast Cancer

Clinical approach: HER2+ cancers are treated with HER2-targeted therapy because:

• These cancers have too many HER2 receptors driving growth
• Targeted drugs can block HER2 signals and slow cancer growth

Treatment options may include:

• Trastuzumab (Herceptin)—an antibody that targets HER2
• Pertuzumab (Perjeta)—another HER2-targeting drug
• Trastuzumab deruxtecan (Enhertu)—a newer targeted therapy
• Often combined with chemotherapy

HR+ AND HER2+ (Both Positive)

Clinical approach: According to NCCN Guidelines for Metastatic Breast Cancer, patients with both HR+ and HER2+ disease may benefit from:

• HER2-targeted therapy PLUS
• Endocrine (hormone) therapy
• This combination approach targets both pathways

Hormone Receptor-Negative (HR-) Breast Cancer

Both ER and PR are negative

Clinical approach: HR- cancers often grow faster and don't respond to hormone therapy, so:

• Chemotherapy is typically the standard first-line treatment
• If HER2+, then HER2-targeted therapy is added
• If triple-negative (HR-, HER2-), immunotherapy or targeted therapy may be considered

---

How Testing Is Done

According to NCCN Guidelines, biomarker testing uses:

• Immunohistochemistry (IHC): A special staining process where a pathologist adds chemical markers to cells and examines them under a microscope
• A biopsy sample from your tumor (required for accurate testing)
• Testing should be done on any new tumors to ensure current information

---

Key Questions to Ask Your Oncologist

Now that you understand what these tests mean, here are specific questions to ask your care team:

1. "What are my specific ER, PR, and HER2 results, and what do they mean for my treatment options?"

2. "Based on my biomarker results, which treatment approach do you recommend, and why?"

3. "Are there any other biomarker tests you recommend (like PIK3CA mutations or tumor mutation testing) that might guide additional treatment options?"

4. "What are the benefits and side effects of the treatments you're recommending for my specific biomarker profile?"

5. "How will we monitor whether my treatment is working, and what happens if my cancer doesn't respond as expected?"

---

Important Context

Your biomarker results are one important piece of your treatment puzzle. Your oncologist will also consider:

• Your overall health and performance status
• Stage of cancer (early vs. metastatic)
• Your personal goals and preferences
• Other tumor characteristics (grade, size)
• Your ability to tolerate specific treatments

Your oncologist will determine the most appropriate approach for YOUR specific case based on the complete clinical picture, not just biomarker results alone.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.